Exchange: NASDAQ·Updated 12:07 PM EST

RAPP News

News
all
press releases
Rapport Therapeutics (RAPP) Shares Sink 20% After Hours
Rapport Therapeutics stock falls after hours as investors assess proposed stock and convertible notes offerings.read more...
Benzinga
Rapport Therapeutics (RAPP) Shares Sink 20% After Hours
Rapport Therapeutics stock falls after hours as investors assess proposed stock and convertible notes offerings.read more...
Benzinga
More News
RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study
The drug met its primary trial goal, producing a statistically significant 3.1-point improvement over placebo on a standard clinician-rated scale that measures the severity of manic symptoms.
Stocktwits
Futures Slip As Korean Data Center IPO Faceplant Revives Tech Rout, French Spread Blows Out
Futures Slip As Korean Data Center IPO Faceplant Revives Tech Rout, French Spread Blows Out US futures are lower, led by the Nasdaq, as Monday's AI relief bounce fizzled overnight after South Korean data-center firm Elice cratered more than 30% in its trading debut, reviving doubts...
Zero Hedge
Rapport Therapeutics Scores Bipolar Mania Breakthrough as RAP-219 Advances Toward Phase 3
Rapport Therapeutics (NASDAQ:RAPP) delivered a major clinical milestone, announcing positive Phase 2 results for RAP-219 in adults experiencing acute bipolar mania. The randomized, double-blind, placebo-controlled trial enrolled 253 adults with bipolar I disorder and met both its primary and secondary endpoints, strengthening the case for a potential new treatment in a field where tolerability remains a significant challenge. With additional Phase 3 programs already underway in epilepsy, Rapport is building a broader development story around a single investigational drug with multiple potential applications.
24-7 Market News
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
Zacks
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Zacks
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.read more...
Benzinga
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
Key PointsCOO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share...
Nasdaq News: Markets
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday
Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat

Advertisement|Remove ads.